Year: 2022

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 18775 DKT 01/12/22 22 / IV 420 420 0.845 100 % 99.887598 18858 DKT 01/03/23 23 / I 700 600 1.300 100 % 99.5041Total 1,120 1,020      The sale will settle 14 October 2022

Press release no 14-2022 Copenhagen, October 12, 2022   Konsolidator adds Single Sign-On as a new security feature Konsolidator has released the new product feature “Single Sign–On” (SSO), which is an extra authentication method that enables users to securely log in to multiple enterprise systems by using just one username and password. Konsolidator strengthened access security with Two Factor authentication in 2020 to help customers increase the security of their accounts, but with SSO activation, customers can now add an additional level of protection for the entire enterprise as SSO allows companies to control user access and deactivation centrally to avoid unintended access when employees leave the company. In addition, SSO makes user management easier and logins faster. The strategic impactAn essential part of Konsolidators...

Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The meeting will be held from Oct. 26-28, 2022. The poster will include preclinical data demonstrating that Kronos Bio’s internally discovered oral CDK9 inhibitor, KB-0742 induced regressions in a preclinical model of MYCN-amplified neuroblastoma tumors and inhibited growth in patient-derived xenograft (PDX) models of transcriptionally addicted Ewing sarcoma (EW) and alveolar...

Announcement no. 15 2022Contain Insider information Copenhagen – 12 October 2022 – Agillic A/S (Nasdaq First North Growth Market Denmark: AGILC)    Agillic raises its financial guidance on Total ARR and Revenue as a result of the latest development in ARR from transactions in particular. The new financial guidance for the full year 2022 is:DKK million  Revenue 61 to 65EBITDA 0 to 3        ARR subscriptions 56 to 60        ARR transactions 12 to 16Total ARR 68 to 76   The previous guidance announced 23 August 2022 was: Revenue: DKK 60 to 64EBITDA: DKK 0 to 3 ARR subscriptions: DKK 56 to 60 ARR transactions:...

Company Announcement, Helsinki, 12 October 2022 at 10 AM (EEST) Nexstim Plc: Managers’ Transactions – Karvinen Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces managers’ transactions as follows: Person subject to the notification requirementName: Mikko KarvinenPosition: Chief Executive Officer Issuer: Nexstim OyjLEI: 743700S7ZI0LNMHZ6Y27Notification type: INITIAL NOTIFICATIONReference number: 20302/5/4____________________________________________ Transaction date: 2022-10-10Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000506811Nature of the transaction: SUBSCRIPTION(X) Linked to stock option programme Transaction details(1): Volume: 8850 Unit price: 2 EURAggregated transactions(1): Volume: 8850 Volume weighted average price: 2 EUR Further information is available on the website...

KRAKOW, Poland, Oct. 12, 2022 (GLOBE NEWSWIRE) — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that it will present clinical data on RVU120 in relapsed/refractory metastatic or advanced solid tumors, preclinical data on RVU120 enhancing antibody-dependent cellular cytotoxicity and discovery, and optimization data on novel MTA-cooperative PRMT5 inhibitors at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium taking place on October 26-28 in Barcelona, Spain. “We are excited to present updated clinical and preclinical data on RVU120 and our novel MTA-cooperative PRMT5 inhibitors at this year’s AACR-NCI-EORTC symposium,” said Hendrik Nogai, M.D., Chief Medical Officer...

Company announcement no 16-2022 Copenhagen, October 12, 2022 Registration of capital increase completed With reference to company announcement No. 14-2022 of September 30, 2022, where Konsolidator secured funding of DKK 5 million, a capital increase of DKK 3 million and a credit facility of DKK 2 million, the registration of the capital increase has been completed. Registration of capital increaseThe capital increase of a nominal amount of DKK 13,568.52 consisting of 339,213 shares each with a nominal value of DKK 0.04 has been registered with the Danish Business Authority. The company will have a registered share capital of nominal DKK 644,667 consisting of 16,116,675 shares and votes after registration of the capital increase. The new shares represent approximately 2 % of Konsolidator’s registered share capital before the capital increase...

CARGOTEC CORPORATION, PRESS RELEASE, 12 OCTOBER 2022 AT 9:30 AM (EEST) Cargotec’s interim report January–September 2022 to be published on Wednesday, 26 October 2022 Cargotec Corporation will publish its interim report January–September 2022 on Wednesday, 26 October 2022 at approximately 1:30 p.m. EEST. The report will be available at www.cargotec.com after publication. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 3:00 p.m. EEST. The event will be held in English. The report will be presented by CEO Mika Vehviläinen and CFO Mikko Puolakka. The presentation material will be available at www.cargotec.com by the latest 2:30 p.m. EEST. The telephone conference, during which questions may be presented, can be accessed with code 4693576# by calling one of the following...

SAMPO PLC                 STOCK EXCHANGE RELEASE         12/10/2022 at 08:30 am Sampo plc’s share buybacks 11/10/2022 On 11/10/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  13,352 44.33 AQEU  32,402 44.35 CEUX  9,587 44.33 TQEX  69,861 44.36 XHELTOTAL 125,202 44.35  *rounded to two decimals                 On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based...